Piñeiro LR, Fernández-Britto RJE, Gómez PI

Idioma: Español
Referencias bibliográficas: 42
Paginas: 37-45
Archivo PDF: 43.92 Kb.

RESUMEN

La aterosclerosis es un proceso de origen multicausal y se acompaña de una gran variedad de manifestaciones clínicas y humorales. Son conocidos los factores de riesgo aterogénicos como dislipidemias, hipertensión arterial, diabetes mellitus, obesidad, tabaquismo, aumento de homocisteína y otros. La aterosclerosis lleva a la cardiopatía isquémica, enfermedad cerebro-vascular, enfermedad renal crónica, enfermedad arterial periférica y aneurismas ateroscleróticos. Es bien conocido que, por estar estrechamente ligada con la sangre y el oxígeno que necesitan todas las células del organismo, deja su huella en casi todos los órganos y tejidos del organismo, produciendo afectación en el sistema nervioso central y por lo tanto, en la esfera cognitiva. Los factores de riesgo ateroscleróticos que pueden afectar la función cognitiva principalmente son: hipertensión arterial, diabetes mellitus, dislipidemia, obesidad, síndrome metabólico, envejecimiento, aumento de la homocisteína sanguínea, aumento del fibrinógeno y tabaquismo. Se hace una revisión actualizada del tema, el cual consideramos de gran interés, para tener en cuenta en la asistencia médica diaria.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fernández-Britto JE, Castillo JA. El Centro de Investigaciones y Referencias de Aterosclerosis de La Habana (CIRAH) (Editorial). Rev Cubana Invest Bioméd. 1998;17(2):101-11.

2. Fernández-Britto JE, Wong R, Contreras D, Nordet P, Sternby NH. Pathomorphometrical characteristics of atherosclerosis in youth. A multinational investigation of WHO/International Society Federation Cardiology (1986-1996), using atherometric system. Nutr Metab Cardiovasc Dis. 1999;9(5):210-9.

3. ————. Aterosclerosis de la juventud (1): patomorfología y morfometría según edad y sexo utilizando el sistema aterométrico. Estudio PBDAY (Pathobiological determinants of atherosclerosis in youth). Estudio multinacional de la OMS/FISC (1986-1996). Base Científica. Clin Invest Arteriosclerosis. 1998;10(5);229-38.

4. Sternby NH, Fernández-Britto JE, Nordet P. Pathobiological determinants of atherosclerosis in youth (PBDAY Study), 1986-96. Bull World Health Organ. 1999;77(3):250-7.

5. Rafnsson SB, Deary IJ, Fowkes FG. Peripheral arterial disease and cognitive function. Vasc Med. 2009;14(1):51-61.

6. Waldstein SR, Tankard CF, Maier KJ, Pelletier JR, Snow J, Gardner AW, et al. Peripheral arterial disease and cognitive function Psychosom Med. 2003;65(5):757-63.

7. Gatto NM, Henderson VW, St John JA, McCleary C, Detrano R, Hodis HN, et al. Subclinical atherosclerosis is weakly associated with lower cognitive function in healthy hyperhomocysteinemic adults without clinical cardiovascular disease. Int J Geriatr Psychiatry. 2009;24(4):390-9.

8. Romero JR, Beiser A, Seshadri S, Benjamin EJ, Polak JF, Vasan RS, et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke. 2009;40(5)1590-6.

9. Verdelho A, Madureira S, Ferro JM, Basile AM, Chabriat H, Erkinjuntti T, et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatr. 2007;78(12):1325-30.

10. Van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study Stroke. 2008;39(10):2712-9.

11. Obisesan TO, Obisesan OA, Martins S, Alamgir L, Bond V, Maxwell C, et al. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc. 2008;56(3):501-9.

12. Suhr JA, Stewart JC, France CR. The relationship between blood pressure and cognitive performance in the Third National Health and Nutrition Examination Survey (NHANES III). Psychosom Med. 2004;66(3):291-7.

13. Gupta R, Solanki RK, Midha P, Dubey V, Pathak V. Association of hypertension and its treatment with dementia and cognitive functioning. Indian Heart J. 2006;58(4):336-40.

14. Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis. 2008;101(3):181-9.

15. Hanon O, Seux ML, Lenoir H, Latour F, Rigaud AS, Forette F. Cognitive functions and hypertension. Arch Mal Coeur Vaiss. 2005;98(2):133-9.

16. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia Vasc Health Risk Manag. 2008;4(2):363-81.

17. Hanon O, Seux ML, Lenoir H, Rigaud AS, Forette F. Prevention of dementia and cerebro protection with antihypertensive drugs. Curr Hypertens Rep. 2004;6(3):201-7.

18. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev. 2006;(2):CD004034.

19. Willis LM, Shukitt-Hale B, Joseph JA. Modulation of cognition and behavior in aged animals: role for antioxidant- and essential fatty acid-rich plant foods. Am J Clin Nutr. 2009;89(5):1602S-1606S.

20. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev. 2003;(4):CD004514.

21. Djuric D, Jakovljevic V, Rasic-Markovic A, Djuric A, Stanojlovic O. Homocysteine, folic acid and coronary artery disease: possible impact on prognosis and therapy. Indian J Chest Dis Allied Sci. 2008;50(1):39-48.

22. Malouf R, Grimley Evans J. The effect of vitamin B6 on cognition. Cochrane Database Syst Rev. 2003;(4):CD004393.

23. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol. 2006;63(11):1551-5.

24. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia Curr Neurol Neurosci Rep. 2007;7 (5):373-80.

25. Bruehl H, Wolf OT, Sweat V, Tirsi A, Richardson S, Convit A. Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 2009;1280:186-94.

26. Diamant M. Brain insulin signalling in the regulation of energy balance and peripheral metabolism Ideggyogy Sz. 2007;60(3-4):97-108.

27. Piñeiro R, Díaz T, Alonso MC. The obesity as a risk factor of type 2 Diabetes mellitus in adolescents. Paediatric Research. 2001;(suppl)49(6):128.

28. Ye J, Kraegen T. Insulin resistance: central and peripheral mechanisms. The 2007 Stock Conference. Report Obes Rev. 2008;9(1):30-4.

29. Butt MU, Zakaria M. Association of common carotid intimal medial thickness (CCA-IMT) with risk factors of atherosclerosis in patients with type 2 diabetes mellitus. J Pak Med Assoc. 2009;59(9):590-3.

30. Dalla Pozza R, Hans Schwarz P, Bonfig W, Netz H, Bectold S. Cardiovascular risk in diabetes childre, Results of a longitudinal study. Horm Res. 2009;72(suppl 3):84.

31. Cerhan JR, Folsom AR, Mortimer JA, Shahar E, Knopman DS, McGovern PG. Correlates of cognitive function in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Invest Gerontol. 1998;44(2):95-105.

32. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008;70(3):193-219.

33. Hwang LL, Wang CH, Li TL, Chang SD, Lin LC, Chen CP, et al. Differences in Hçhigh-fat diet-induced obesity, metabolic alterations and learning, and synaptic plasticity deficits in mice. Obesity (Silver Spring). 2009;Sep 3(Pub Med).

34. Han SH, Sakuma I, Shin EK, Koh KK. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies Prog Cardiovasc Dis. 2009;52(2):126-40.

35. Pregelj P. Involvement of cholesterol in the pathogenesis of Alzheimer's disease: role of statins. Psychiatr Danub. 2008;20(2):162-7.

36. Carlsson CM, Nondahl DM, Klein BE, McBride PE, Sager MA, Schubert CR, et al. Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer Dis Assoc Disord. 2009;23(1):11-7.

37. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71 (5):344-50.

38. Rapp JH, Pan XM, Neumann M, Hong M, Hollenbeck K, Liu J. Microemboli composed of cholesterol crystals disrupt the blood-brain barrier and reduce cognition. Stroke. 2008;39 (8):2354-61.

39. Liu CY, Zhou HD, Xu ZQ, Zhang WW, Li XY, Zhao J. Metabolic syndrome and cognitive impairment amongst elderly people in Chinese population: a cross-sectional study. Eur J Neurol. 2009;16(9):1022-7.

40. Farr SA, Yamada KA, Butterfield DA, Abdul HM, Xu L, Miller NE, et al. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology. 2008;149(5):2628-36.

41. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, et al. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc. 2007;55(5):700-7.

42. Mangiafico RA, Sarnataro F, Mangiafico M, Fiore CE. Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and D-dimer levels. Age Ageing. 2006;35(1):60-5.